858 Therapeutics, Inc.
San Diego, US · 3 known investors
858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors. Its lead program, ETX-19477, is an oral, selective PARG inhibitor being tested in a Phase 1/2 clinical study.
Founders & leadership
SJ
Stafford JeffreyFounder
JV
James VealExecutive
KB
Katherine Bell-McGuinnExecutive
Board
MM
Monal MehtaBoard director
AB
Ali BehbahaniBoard director
CO
Clare OzawaBoard director
JH
Jane HuangBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$65.2M disclosed across 3 rounds · 2020–2024
▶$25.2MraisedJul 2024 · 12 investors · PharmaceuticalsRule 506(b)
▶$25.2MraisedJul 2024 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James VealExecutive Officer
- Jane HuangDirector
- Monal MehtaDirector
- Stafford JeffreyExecutive Officer, Director
- Ali BehbahaniDirector
- Katherine Bell-McGuinnExecutive Officer
- Clare OzawaDirector
- Offering amount
- $50.4M
- Amount sold
- $25.2M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMay 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$20MraisedMay 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carlo RizzutoDirector
- Ali BehbahaniDirector
- Jeffrey A. StaffordExecutive Officer, Director
- James VealExecutive Officer
- Clare OzawaDirector
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$20.1MraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$20.1MraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clare OzawaDirector
- Bradley J. BolzonDirector
- James VealExecutive Officer
- Offering amount
- $37.5M
- Amount sold
- $20.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does 858 Therapeutics, Inc. do?
- 858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors. Its lead program, ETX-19477, is an oral, selective PARG inhibitor being tested in a Phase 1/2 clinical study.
- Who founded 858 Therapeutics, Inc.?
- 858 Therapeutics, Inc. was founded by Stafford Jeffrey.
- Who are 858 Therapeutics, Inc.'s investors?
- 858 Therapeutics, Inc.'s investors include New Enterprise Associates (NEA), Versant Venture Capital, Versant Ventures.
- How much funding has 858 Therapeutics, Inc. raised?
- 858 Therapeutics, Inc. has disclosed $65.2M raised across 3 rounds.
- Where is 858 Therapeutics, Inc. headquartered?
- 858 Therapeutics, Inc. is headquartered in San Diego, US.